China Health Care Data Insights: Online sales of GLP-1 therapies remain robust; Mazdutide saw upward momentum in sales

Issuing time:2025-07-31 00:00Author:DataBurning

Online sales of GLP-1 therapies continued to accelerate across major e-commerce platforms in China. According to DataBurning's

tracking, in the 30-day period ending 2025/7/13:


[Rybelsus] (semaglutide for glycemic control, Novo Nordisk) generated ~RMB 140 mln in GMV across major e-commerce platforms in

China, representing a 177% y/y increase. GMV for 25H1 has already matched the full-year total for 2024.


[Wegovy] (semaglutide for weight loss, Novo Nordisk) recorded over RMB 7 mln in GMV. Novo Nordisk received regulatory approval for

Wegovy as a weight loss treatment in China, and since its launch in November 2024, Wegovy has achieved cumulative GMV of ~RMB 35

mln.


[Zepbound] (tirzepatide for weight loss, Eli Lilly) achieved GMV of over RMB 30mln. Eli Lilly received regulatory approval for

Zepbound as a weight loss treatment in China, and since its launch in January 2025, Zepbound has achieved cumulative GMV of nearly

RMB 80 mln.


[Mazdutide / Xinermei] (Innovent Biologics) recorded over RMB 3mln in GMV.


*On 2025/6/27, Mazdutide (commercial name: Xinermei), co-developed by Innovent Biologics and Eli Lilly, was officially approved in

China for chronic weight management in adults with overweight or obesity. The product is now available on major e-commerce

platforms.


Explore How DataBurning Can Be Your Strategic Partner
in Uncovering Opportunities

DataBurning
Legal Information
Contact Us
Tel: +86-010-82866618
Beijing Office
Room 095, No. 1-325, 3rd Floor, Business Center,
No. 9 Wangjing Street, Chaoyang District, Beijing, China


Shanghai Office
Room 303, Central Park Jing’an, No. 329 Hengfeng Road,
Jing’an District, Shanghai, China